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Abstract  
Objectives 
Adenoma detection rate (ADR) is an important quality marker at lower gastrointestinal 
endoscopy. Higher ADRs are associated with lower post-colonoscopy colorectal cancer 
rates. The English flexible sigmoidoscopy screening programme (BowelScope), offers a one-
off flexible sigmoidoscopy to individuals aged 55. However, variation in ADR exists. Large 
studies have demonstrated improved ADR utilising Endocuff Vision™ (EV) within 
colonoscopy screening but there are no studies within flexible sigmoidoscopy. We sought to 
test the effect of EV on ADR in a national flexible sigmoidoscopy screening population. 
Design 
B-ADENOMA was a multicentre, randomised controlled trial involving 16 English 
BowelScope screening centres. Individuals were randomised to EV-assisted BowelScope 
(EAB) or Standard BowelScope (SB). ADR, polyp detection rate (PDR), mean adenomas per 
procedure (MAP), polyp characteristics and location, participant experience, procedural 
time and adverse events were measured. Comparison of ADR within the trial with national 
BowelScope ADR was also undertaken. 
Results 
3222 participants were randomised (53% male) to receive EAB (n=1610) or SB (n=1612). 
Baseline demographics were comparable between arms. ADR in the EAB arm was 13.3% and 
in the SB arm was 12.2% (p=0.353). No statistically significant differences were found in 
PDR, MAP, polyp characteristics or location, participant experience, complications or 
procedural characteristics. ADR in the SB control arm was 3.1% higher than the national 
ADR.  
Conclusion 
EV did not improve BowelScope ADR when compared to standard BowelScope. ADR in both 
arms was higher than the national ADR.  Where detection rates are already high, EV is 
unable to improve detection further.  
 
 
 
 
 
 
 
 
 
Trial Registration 
clinicaltrials.gov NCT03072472  
International Standard Randomised Controlled Trials Number ISRCTN30005319  
UK National Health Service NIHR portfolio CPMS ID 33224 
 
Summary  
What is already known about this subject? 
We searched Medline and PubMed for publications in humans up to July 2019, using the 
terms ‘Endocuff’ and ‘Endocuff Vision’. We identified 11 RCTs and 4 case series studies. 
This included our own group’s study (the ADENOMA study) published in 2018. 2 other 
RCTs and the ADENOMA study utilised the Endocuff Vision™ (EV) device whilst the 
remainder used the original Endocuff™. The ADENOMA trial demonstrated an increase in 
ADR of 4.7% overall, driven by a bowel cancer screening subgroup increase of 10.8%. One 
EV study demonstrated an improvement in ADR of 7.8% which was not statistically 
significant but accompanied by a significant increased polyp detection rate of 11.9%. A 
single centre trial showed no increase in ADR with EV, influenced by exceptionally high 
ADR in both trial arms. 
 
Of the RCTs which utilised the original Endocuff™ device, 3 showed increases in ADR of 
3.3%, 8.9% and 14.7% respectively, one reported a lower adenoma miss rate of 23.7% but 
the rest did not demonstrate any significant difference in ADR. Findings from the case 
series reported improved mean number of adenomas detected per procedure and 
adenoma detection rates of up to 44.7%.  
 
What are the new findings? 
To the best of our knowledge this is the first trial of EV in a flexible sigmoidoscopy 
population and it is the largest endoscopy randomised controlled device trial ever 
reported. The trial did not show an increase in ADR in the EV arm of this average risk 
population, however both the control arm ADR (12.2%) and the intervention arm ADR 
(13.3%) were significantly higher than the ADR in the broader national BowelScope 
programme (9.1%). EV was well tolerated.  
 
How might it impact on clinical practice in the foreseeable future?                                      
EV has not been proven to increase ADR in an average risk population such as those 
undergoing flexible sigmoidoscopy screening. This contrasts with the increase in ADR in 
individuals at increased risk of adenomas (those who are faecal occult blood positive). 
Where ADR is high it is unlikely that EV can increase detection further however it may be 
of value to endoscopists with lower detection rates. Future EV research should focus on 
which specific endoscopy populations EV will benefit.  
 
 
INTRODUCTION  
16,000 people die in the United Kingdom (UK) annually from colorectal cancer (CRC) with 
1.4 million cases worldwide in 2012(1). The English National Health Service (NHS) Bowel 
Cancer Screening Programme (BCSP) delivers two CRC screening programmes – a faecal 
occult blood (FOBt) based programme for people aged 60 -74 and one-off flexible 
sigmoidoscopy (FS) examination for people age 55 (termed BowelScope)(2). Evidence 
demonstrates that one-off FS between ages 55 to 64 can reduce CRC incidence by 23% and 
deaths by 31% (3). Flexible sigmoidoscopy and subsequent polypectomy interrupts the 
adenoma-carcinoma sequence, preventing progression to CRC(4). At BowelScope, if > 3 
adenomas, a polyp with villous histology or high grade dysplasia, a polyp of >10mm in size, 
>20 hyperplastic polyps above the rectum, or a polyp which cannot be removed due to 
patient factors are found, individuals are referred for full  colonoscopy. BowelScope is 
predicated on the ability of the investigation to maximise detection of adenomas present in 
the examined part of the colon. Details of BowelScope have been described elsewhere (2,5). 
The most widely used measure of mucosal visualisation at lower gastrointestinal endoscopy 
is Adenoma Detection Rate (ADR)(6,7). ADR in BowelScope is lower than in FS trials, varying 
between centres and endoscopists(3,5,8,9). Factors influencing ADR at lower GI endoscopy 
include withdrawal time, use of antispasmodic medication, quality of bowel preparation 
and, crucially, adequate visualisation of the proximal aspect of mucosal folds(10,11). One 
approach to improve detection is using devices to hold back folds and enhance mucosal 
visualisation. Endocuff Vision™ (EV)(Figure 1), is a polypropylene device mounted onto the 
distal tip of a colonoscope(12). EV consists of a fixed portion and a row of eight soft 
projections which fold backwards during insertion but pull forwards during withdrawal to 
evert and slowly release colonic folds. This is a second-generation device with the earlier 
Endocuff™ (EC) improving ADR in some colonoscopy studies(13-15).  
A recent multicentre randomised controlled trial (RCT), the ADENOMA trial, undertaken in 
participants attending for colonoscopy, demonstrated a significant increase in ADR using 
EV(16). ADENOMA demonstrated a 4.7% higher ADR in the intervention arm (p=0.02) driven 
by a 10.8% higher ADR (p<0.001) in FOBt positive BCSP participants undergoing 
colonoscopy. The greatest benefit was in the left colon, considered to be due to its 
increased tortuosity and prominent folds. No studies have investigated EV in FS. The effect 
of a device on total procedure time, completion rate, indirect health economic effects of 
finding more polyps and effect of a device on the experience of participants, particularly 
procedural comfort are important. The acceptability of an investigation is vitally important 
to screening tests(17,18). B-ADENOMA was an RCT comparing FS with and without EV in the 
English BowelScope screening programme. B-ADENOMA sought to determine the effect of 
EV on ADR, other detection markers and any other impact on BowelScope procedures.  
 
METHODS 
Study design 
B-ADENOMA was a multicentre RCT recruiting patients from 16 hospitals in England 
between February 2017 and February 2018. All hospitals delivered dedicated BowelScope 
lists. A short learning curve has previously been identified for EV use, therefore all 
endoscopists had to complete a minimum of 10 EV procedures prior to the study (16,19).  
The B-ADENOMA protocol has been published (20), registered with clinicaltrials.gov 
NCT03072472, International Standard Randomised Controlled Trials Number 
ISRCTN30005319 and adopted onto the UK NHS NIHR portfolio (CPMS ID 33224). A 
favourable ethical opinion was received from UK West Midlands - Solihull Research Ethics 
Committee. 
 
Participants 
BowelScope screening invites all 55-year-olds for a one-off procedure; however, individuals 
between 55 and 61 years may contact screening centres and opt into BowelScope. 
Participants receive a BowelScope appointment at their closest local screening hospital. B-
ADENOMA recruited BowelScope individuals aged 55 to 61 who were able to give informed, 
written consent. Exclusion criteria included absolute contraindications to FS, known or 
suspected bowel obstruction, colonic strictures, polyposis syndromes, known severe 
diverticular segment, active colitis, anticoagulation precluding polypectomy and pregnancy. 
BowelScope procedures are done without sedation. Reasons to withdraw participants from 
the trial after randomisation were withdrawal of consent, or new diagnosis of a polyposis 
syndrome. These individuals were excluded due to the different natural history of 
development of these polyps and significant malignant potential. All inclusion and exclusion 
criteria can be found in the protocol summary on the ISRCTN registry.  
Standard BowelScope (SB) was undertaken in accordance with standard NHSBCSP 
procedures (22). Data were recorded on the Bowel Cancer Screening System (BCSS) 
database from which trial data were also reported.  
Endocuff Vision™ - assisted BowelScope (EAB) was performed using the same protocol as SB 
with the following modifications: once in procedure room, endoscopist and staff were made 
aware of randomisation outcome and EV was attached to the tip of the endoscope 
according to manufacturer’s instructions.  
Removal of EV during BowelScope was advised if the endoscopist felt the device was 
hindering safe progression. Reasons for this included acute angulation in fixed sigmoid 
colon, colonic stricture, new diagnosis of malignancy or new diagnosis of active colitis 
(endoscopist concern over risk of mucosal damage).  
Randomisation and masking 
Stratified randomisation based on age, sex and hospital site was performed using a dynamic 
allocation algorithm created by the North Wales Organisation for Randomised Trials in 
Health Clinical Trials Unit using a computerised internet-based platform (21). It was not 
possible to blind endoscopists, endoscopy staff, research teams or participants to 
randomisation allocation as EV is visible on the end of the colonoscope.  
 
 
Outcomes 
The primary outcome was the proportion of participants with one or more colorectal 
adenomas detected at BowelScope as measured by the ADR.  
Secondary outcomes were: Polyp Detection Rate (PDR);  Sessile serrated polyps detection 
rate; Advanced adenoma detection rate; Cancer (cancerous polyps (those found to be 
cancerous on histological assessment) or endoscopic cancer (lesion felt to be a cancer by the 
endoscopist)) detection rate; Mean number of Adenomas detected per Procedure (MAP); 
Mean number of Polyps detected per Procedure (MPP); Mean number of advanced 
adenoma detected per procedure; Polyp size (measured in mm); Polyp morphology (Paris 
classification); Polyp location (transverse colon, splenic flexure, sigmoid colon, or rectum); 
Procedure withdrawal time (in minutes – recorded in procedures where no lesions detected 
to remove confounder of time taken for lesion removal); Procedure completion time (in 
minutes – recorded in procedures where no lesions detected to remove confounder of time 
taken for lesion removal); Reach of  procedure (transverse colon, splenic flexure, sigmoid 
colon, or rectum); Discomfort assessed by patient (0 to 9 scale); Discomfort assessed by 
nurse (0 to 4 scale); Complications rate (adverse events related to procedure); Rate of 
conversion colonoscopies generated; Rate of EV change (how often was cuff removed).  
Additional explanatory analyses included: comparison of ADR of first 20% of participants 
scoped by each endoscopist compared to last 20% of participants scoped by each 
endoscopist in each arm to identify changes due to learning curve effect; comparison of 
endoscopist ADR pre-trial and within trial; post hoc explanatory comparison of ADR within 
the trial with NHSBCSP data were also undertaken.  
The modified Gloucester score was used by nursing staff to record patient comfort as per 
BowelScope practice and a truncated Nurse-Assessed Patient Comfort Score (NAPCOMS) 
was given to participants pre-discharge and for completion at 24 hours(23,24). Participants 
were followed up for 14 days for late complications and to check polyp histology. Adverse 
Events (AEs) or Serious Adverse Events (SAEs) were defined a priori in the trial protocol and 
reported to the Data Monitoring Committee (DMC), with severity and relation to EV 
reviewed by 2 independent clinicians. A full list of endpoints can be found in the protocol 
summary on the ISRCTN registry.  
 
Statistical analysis 
This trial was powered to detect a difference in ADR at BowelScope between EAB and SB. 
National BowelScope ADR at trial commencement was 8.8% (BCSP national data). This figure 
was used to power the trial; however subsequent analyses used the more up-to-date 
published national ADR of 9.1%(9). An increase in ADR of 3% was agreed to be clinically 
significant. Using a two-sided test with 5% significance level and 80% power, the trial 
required 1611 participants per group to detect a statistically significant difference in 
proportion of participants with adenomas, as measured by ADR, between trial arms.  
All analyses were conducted on an intention-to-treat basis. Tests of non-inferiority 
(procedure withdrawal and completion time) were analysed on both per protocol and 
intention to treat basis. Secondary analyses (polyp detection rate, polyp location, comfort 
scores) were adjusted for multiple comparisons using Bonferroni correction. All other 
analyses were performed using a 5% significance level with 95% confidence intervals are 
presented. All statistical tests and confidence intervals were two-sided.  A fully defined 
statistical analysis plan was written and agreed prior to completion of data collection. When 
conducting analysis, trial statisticians were blinded as to which arm was which. 
For the primary binary outcome, of whether an adenoma was detected or not, logistic 
regression was employed to compare the difference in primary outcome between groups, 
taking into account randomisation stratification variables (endoscopy site, sex and age 
group). Similarly, for secondary outcomes of polyp detection rates, sessile serrate polyps, 
advanced adenoma and cancer, logistic regression was employed to compare the difference 
between EAB and SB group adjusting for the effects of the randomisation stratification 
variables (endoscopy site, sex and age).  
The secondary outcomes based on the number of adenomas, polyps and advanced 
adenomas detected were analysed using Analysis of Variance (ANOVA) models which 
adjusted for the effects of randomisation stratification variables. Secondary outcomes 
concerning characteristics of the detected polyps: polyp size, morphology and location were 
compared between the EAB and SB group. For polyp size, an ANOVA was conducted and for 
polyp morphology and location, multinomial logit regressions were conducted. 
Non-inferiority testing, for withdrawal and completion times involved using an ANOVA and a 
non-inferiority margin of 1 minute, which was deemed a minimal clinically important 
difference. To determine whether the examination extent of EAB group was inferior to SB, 
descriptive analysis was used where the proportion of procedures for each extent of 
examination was calculated for both groups and clinician judgment used to determine if 
they were inferior. A Chi-squared test was also undertaken to compare examination extent 
between groups. Non-inferiority testing for participant experience of comfort involved 
conducting ANOVAs using a non-inferiority margin of one point for participant experience of 
comfort. Non-inferiority testing for complication rates involved conducting a logistic 
regression with a non-inferiority margin of 10%.  
Logistic regression was employed to compare the rate of conversion colonoscopies 
generated by EAB and SB groups. Repeated measures t-tests were computed to examine 
comparisons and relationships between ADR for the first 20% of procedures versus ADR for 
the last 20% procedures.  
Dropouts were defined as patients who were randomised to enter the study but for some 
reason did not complete it (i.e. withdrew). Given the low percentage of missing data the 
complete case approach to dealing with missing data was employed in line with the recent 
recommendations of best practice (25). As this trial was aimed to detect differences in 
detection rates at Bowelscope as affected by EV the detection rates for subsequent 
colonoscopy procedures were not measured.  
Patient and public involvement  
Patient and public involvement informed the development, conduct and reporting of this 
study with a patient representative on the trial steering committee. Input was also obtained 
from local patient groups and patient and public representation on the National Cancer 
Research Institute CRC screening and prevention group.  
 
RESULTS 
6579 individuals were identified and assessed for trial eligibility between 14th February 2017 
and 13th February 2018 (Figure 2). 3357 individuals were excluded with the most common 
reasons being ineligibility (438), not attending for BowelScope (214), declining the study 
(1485), individuals who were not recruited at procedure e.g. unavailable research staff (899) 
and procedure cancellation (292). 3222 individuals were randomised into the study with one 
found to be ineligible post randomisation. 
Patient demographics were balanced across arms. The mean age of participants was 55 
years.  53% of participants were male and 22% had prior abdominal surgery (Table 1). 
Dropout rates were comparable across arms EAB (0.4%, n= 7), SB (0.3%, n = 5). Data from 
participants (n=12) who dropped out were not analysed; the percentage of missing data was 
0.33% across the analysed dataset. 
 
 
EAB (n=1609) (%) SB (n=1612) (%) 
Sex Female 757 (47) 758 (47) 
Male 852 (53) 854 (53) 
Previous abdominal 
surgery 
No 1243 (77.3) 1276 (79.2) 
Yes 365 (22.7) 334 (20.7) 
Unknown 1 (0.1) 2 (0.1) 
 
Table 1: Summary of Participant Characteristics 
 
No significant difference was demonstrated in the primary outcome. ADR in EAB and SB 
arms was 13.3% and 12.2% respectively. Results of logistical regression analyses for other 
detection markers were adjusted to account for randomisation stratification variables (age 
group, sex and endoscopy site) and are summarised in Table 2. 
 
 
 
 
 
 
EAB % (n#) 
N=1578 
SB (%, n#) 
N=1578 
Odds 
Ratio 
95% CI Odds 
Ratio 
p value 
Adenoma Detection Rate 
(ADR) 
13.3 (209) 12.2 (193) 1.11 0.90 - 1.37 0.353 
Polyp Detection Rate 
(PDR) 
28.6 (451) 26.6 (420) 1.11 0.89 - 1.39* 1* 
Sessile Serrated Polyps 0.3 (5) 0.3 (4) 1.32 0.34 - 5.42 0.686 
Advanced Adenoma 6.1 (95) 5.0 (80) 1.23 0.90 - 1.69 0.200 
Cancer 0.2 (3) 0.4 (6) 0.48 0.10 - 1.85 0.292 
* In accordance with the pre-defined statistical analysis plan only the key secondary 
analyses were adjusted for multiple comparisons.  
 #Raw frequency 
Table 2: Summary of Detection Rate Results from the Logistic Regression and adjusted to 
account for randomisation stratification variables (age group, gender and endoscopy site) 
 
Results for the number of lesions detected using ANOVA and adjusted to account for 
randomisation stratification variables (age group, gender and endoscopy site) are 
summarised in Table 3. 
 
 EAB  
(Mean, SD, N) 
SB  
(Mean, SD, N) 
Mean 
Difference 
95% CI Mean 
Difference 
p value 
Mean 
Number of 
Adenomas  
0.23, 0.47,  
1578 
0.21, 0.43,  
1578 
0.02 -0.01 - 0.05 0.153 
Mean 
Number of 
Polyps  
0.53, 0.92,  
1578 
0.49, 0.85,  
1578 
0.04 -0.02 - 0.12 0.190 
Mean 
Number of 
Advanced 
Adenomas  
0.07, 0.28, 
1578 
0.06, 0.25, 
1578 
0.01 -0.02 - 0.10 0.216 
 
Table 3: Summary of the Quantity of lesions detected Results  
 
Regarding characteristics of the detected polyps, no statistically significant differences were 
observed between EAB and SB groups for the size of polyps detected, 4.68mm vs 4.79mm, 
mean difference = -0.11, p = 0.635, 95% CI [-0.58, 0.35]. Similarly, there were no statistically 
significant differences between the EAB and SB groups for polyp morphology, χ2(6)= 8.04, p 
= 1 (Table 4) and  polyp location, χ2 (4)= 3.88, p = 1 (Table 5). 
  
 EAB (%) SB (%) 
Ip 31 (6.8%) 30 (7.0%) 
Ips 36 (7.9%) 28 (6.6%) 
Is 
244 (53.6%) 
209 
(48.9%) 
0-lla 
136 (29.9%) 
156 
(36.5%) 
0-IIa/c 2 (0.4%) 3 (0.7%) 
0-llb 5 (1.1%) 1 (0.2%) 
0-llc 0 (0%) 0 (0%) 
0-llc/lla 1 (0.2%) 0 (0%) 
 
Table 4: Summary of the modal  polyp morphology for each procedure as a function of 
group 
 
 
 EAB (%) SB (%) 
Rectum 
184 (40.3%) 
176 
(41.0%) 
Sigmoid 
232 (50.1%) 
212 
(49.4%) 
Descending 35 (7.7%) 33 (7.7%) 
Splenic flexure 6 (1.3%) 7 (1.6%) 
Transverse 0 (0%) 1 (0.2%) 
 
Table 5: Summary of the modal  polyp location for each procedure as a function of group 
 
Analyses of withdrawal time and overall procedure time (in procedures where no lesions 
were detected), demonstrated no inferiority of EAB relative to SB. The difference in 
withdrawal duration between the EAB group (mean = 3.32, SD =2.05) and the SB group 
(mean = 3.44, SD =2.00) was -0.11 minutes, 95% CI [-0.25, 0.03] which did not cross the 
specified non-inferiority boundary of 1 minute. The difference in procedure duration 
between the EAB group (mean = 7.80, SD =3.49) and the SB group (mean  = 8.03, SD=3.69) 
was -0.23 minutes, 95% CI [-0.48, 0.03] which also did not cross the specified non-inferiority 
boundary of 1 minute. Intention to treat and per protocol analyses were comparable, since 
there were only 5 protocol deviations: three in EAB and two in SB. 
The reach of the procedures for the EAB and SB group are summarised in Table 6. There was 
a statistically significant difference in extent reached, as judged by endoscopist, between 
EAB and SB, χ2(4) = 18.99, p < 0.001 with further extent reached in the SB arm. Post-hoc 
testing showed that there were statistically significant differences between EAB and SB for 
sigmoid, χ2(1) = 9.81, p = 0.002; splenic flexure, χ2(1) = 6.72, p = 0.010 and transverse χ2(1) = 
6.13, p = 0.013 extent. 
 EAB (%) SB (%) 
Rectum 7 (0.4) 7 (0.4) 
Sigmoid 372 (23.2) 301 (18.7) 
Descending 762 (47.6) 738 (45.9) 
Splenic Flexure 367 (22.9) 432 (26.9) 
Transverse 93 (5.8) 129 (8.0) 
 
Table 6: Anatomical location, as judged by endoscopist, reached during procedure as a 
function of group 
 
Analyses of comfort demonstrated non-inferiority of EAB compare to SB. Greater discomfort 
was reported by patients (+0.26 point, 95% CI [0.1, 0.43]) and endoscopy nursing staff 
(+0.11 point, 95% CI [0.03, 0.19]) in EAB arm compared to SB arm, however although these 
differences were statistically significant, they did not reach the level of clinical significance 
as agreed pre-trial, which was set at 1 point of difference on both assessment scales. 
Complication rates (adverse events related to procedure) were identical between the EAB 
(0.3%) and SB groups (0.3%) hence non-inferiority of EAB compare to SB was demonstrated. 
Logistic regression adjusting for randomisation stratification variables revealed no 
statistically significant differences in the number of conversion colonoscopies generated 
between the EAB (8.4%) and SB (6.8%) groups (OR = 1.27, 95% CI [0.97, 1.67]). As a 
consequence, there was also no difference in workload of colonoscopy or surveillance 
generated based on polyp follow up by guidelines(26). The rate of EV exchange in the EAB 
group was 4.21% (95% CI [2.97, 5.95]. Endoscopists performed procedures using both SB 
and EAB and the distribution of number of procedures performed is depicted in Figure 3. 
There was no difference at the level of  individual endoscopists between ADR 6 months pre-
trial and the ADR of those endoscopists in the control arm (SB) of the trial, 10.1% vs. 11.4%, 
t (44) = 0.93, p = 0.355, mean difference = 1.3%, 95% CI [-0.01, 0.04]. For the EAB arm, there 
was a statistically significant difference in ADR for the first 20% of patients compared to the 
last 20% of patients per endoscopist: 8.6% vs 16.6%, t (51) = 2.23, p = 0.030, mean 
difference = 8.0%, 95% CI [0.81, 15.09]. For the SB arm, there was no statistically significant 
difference in ADR for the first 20% of patients compared to the last 20% of patients per 
endoscopist: 9.2% vs 14.2%, t (51) = 1.77, p = 0.083, mean difference = 5.0%, 95% CI [-0.68, 
10.59]. However, although this difference was not statistically significant, it is substantial, 
especially given that a difference of 3% or greater had been deemed clinically significant. 
Furthermore, further explorative analysis (shown in Figure 4) strongly suggests that there is 
evidence for a trial progression effect in the both the EAB and SB groups; i.e in both arms, 
the ADR rose as recruitment to the trial proceeded. 
 
DISCUSSION 
B-ADENOMA was a multicentre RCT delivered across 16 English endoscopy units. This is, to 
our knowledge the largest endoscopy device trial ever conducted. There are no other trials 
examining the use of EV during flexible sigmoidoscopy. The trial did not demonstrate a 
significant difference in ADR detection between EAB and SB in the English NHS BowelScope 
Flexible Sigmoidoscopy Cancer Screening Programme.  
EV previously demonstrated improved detection at colonoscopy in the ADENOMA trial but 
only amongst participants recruited through the BCSP and thus FOBt positive (16) – i.e. a 
population with high rates of pathology. No increase in detection was demonstrated in an 
average risk population in the ADENOMA trial. BowelScope invites unselected asymptomatic 
55-year olds who are at average population risk of colorectal neoplasia.  
It is important to explore why EV improves detection in some settings and not others. ADR 
in the control arm of this study was much higher than in standard BowelScope practice and 
It is likely that the high detection rates of pathology in the control arm could not be 
improved upon with EV. At the beginning of this study, ADR in the national BowelScope 
programme was 8.8% (Public Health England figures) and, more recently, several years into 
the programme, had only risen to 9.1% (9). The high control arm ADR of 12.2 % in this trial is 
well above (3.1% higher) national ADR and is likely that this high ADR meant that EV was 
unable to confer additional improvements in ADR. In contrast to the ADENOMA trial, a 
single centre UK EV study demonstrated no difference in ADR using EV in FOBt positive 
screening patients undergoing colonoscopy (19). In that trial, ADR in the control arm was 
much higher (63%) than national figures. Similarly, a Netherlands study, whilst using the 
original Endocuff™ (EC), found a higher than expected ADR in the control arm (52%) and did 
not see an increase in ADR when EC was used(27). These results demonstrate a consistent 
pattern: where control arm ADR is high (higher than reported ADR in those populations) the 
intervention arm (EV) does not demonstrate an increase in ADR. In any population 
endoscoped there will be a ceiling where all present polyps have been detected and the 
addition of a device or technology to improve detection will not be able to raise that ceiling 
and increase detection further. In 3 other trials utilising the original EC where baseline ADRs 
were comparatively low (13.5%, 20.7%, 26.3% respectively), ADR improvements were 
demonstrated(13-15). EV and the original EC are not the same device so direct comparisons 
are not possible, however these findings reinforce the same message that low ADR may be 
improved but there will be a level at which further improvement is not possible.  
High ADRs seen in the control group arms of the current and previous trials may be 
influenced by high ability of endoscopists operating in centres participating in clinical 
research or influenced by research causing a change in practice(19,27). Individuals who 
agree to participate as endoscopists in research may self-select and be detectors with higher 
performance levels. This principle was suggested by the Netherlands study (27) where it was 
noted that endoscopists who had a high ADR prior to the use of EC benefitted little from 
addition of the device. Change in behaviour amongst practitioners participating in trials is 
well recognised. Whilst the Hawthorne effect refers to changes in behaviour of individuals 
when they are being studied, it may be that endoscopists participating in research change 
practice and become more thorough in their mucosal inspection with or without device 
enhancement leading to above normal performance (28,29). It is also possible that 
endoscopists performing both control and intervention endoscopies change their technique 
both with and without the EV. This effect was suggested in a pilot study where an increase 
in ADR using EV in a colonoscopy screening population persisted when EV was no longer 
used when compared to the period before introduction of the device, although this 
difference did not achieve statistical significance(12). The current trial demonstrates 
ongoing rise in ADR throughout the study providing evidence that endoscopist practice 
changed throughout the trial. 
A number of patient factors are known to affect polyp prevalence including sex, age, 
ethnicity, smoking and obesity(9,30). This was a multi-site study of 16 centres across wide 
English geography with equivalent characteristics across the two arms so this is unlikely to 
have influenced the outcome. We have no evidence to suggest the population studied was 
unrepresentative of the English BowelScope screened population with pre-trial ADR for 
participating sites comparable to national figures. By randomising by participant and not 
endoscopist, this trial has demonstrated the effect of EV on detection. An alternative could 
have been to employ a cluster methodology whereby endoscopists rather than participants 
were randomised and only performed either EAB or SB. This could potentially have limited 
the influence of practice changes using a device being employed without the device, 
however this could have introduced other confounders around endoscopist characteristics, 
and we believe the current trial design to be better. If the true difference between the 
groups was smaller than anticipated (e.g. 1.1% as seen rather than the 3% used for power 
calculation) the study would not have been adequately powered to demonstrate statistical 
significance. However, were this to be the case, the clinical significance of a 1% increase in 
ADR would be small and the authors would consider this not to be a clinically important 
value. 
Comfort, procedural time and complications rates are crucial to the success of screening 
procedures which must be effective, safe and acceptable to the screened population 
(17,18). In our study, EV was associated with a statistically significant increase in participant 
and endoscopy nurse reported discomfort. However, this was not deemed clinically 
significant as set out by pre-trial levels for non-inferiority analysis of 1 point on the 0-9-point 
modified NAPCOMS score used by participants and the 0-4 point modified Gloucester scale 
used by endoscopy nursing staff. EV demonstrated a trend towards shorter withdrawal and 
overall procedural times, consistent with other studies. EV was not associated with an 
increase in complications(12,27).  
We summarise that EV does not increase detection in an average risk population amongst 
endoscopists who already have high ADRs. It is possible that endoscopists with ADRs more 
consistent with or below national detection rates might benefit from EV use but we are 
unable to prove that assertion. It should be noted that whilst EV did not enhance detection, 
although the extent of the procedure was less with EV, this did not equate to a reduction in 
ADR. EV was safe and not associated with any increase in complication rates. Patient 
comfort was not adversely affected significantly. 
B-ADENOMA is to our knowledge the largest endoscopy device trial ever reported and it 
recruited from 16 units in half the anticipated time of nine rather than 18 months.  This 
study demonstrates the ability of a well-motivated network of endoscopy units to achieve 
rapid large-scale recruitment.  
 
CONCLUSION 
The B-ADENOMA trial did not demonstrate increased detection with EV in an average risk 
population undergoing flexible sigmoidoscopy. The ADR in both the control arm and the 
intervention arm were significantly higher than in standard BowelScope flexible 
sigmoidoscopy screening practice.    
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